Study on the Safety and Effectiveness of Mosunetuzumab and Polatuzumab Vedotin for B-Cell Non-Hodgkin Lymphoma

Inclusion Criteria

• Have a performance status score of 0, 1, or 2, indicating full activity or some restriction in strenuous activities.
• Have a confirmed diagnosis of follicular lymphoma, diffuse large B-cell lymphoma, or mantle cell lymphoma.
• Have received at least one previous treatment that included anti-CD20 therapy for diffuse large B-cell lymphoma or follicular lymphoma.
• For mantle cell lymphoma, have received at least two previous treatments, including anti-CD20 therapy, a BTK inhibitor, and either anthracycline or bendamustine.
• Cancer must have returned after responding to previous treatments for at least 6 months, or not responded to previous treatments.
• Have measurable cancer, with at least one tumor that can be measured by scans.
• Have adequate blood, kidney, and liver function.

Exclusion Criteria

• Have had previous treatment with Mosunetuzumab or similar drugs.
• Have had previous treatment with Polatuzumab Vedotin.
• Have more than mild nerve damage.
• Have used any monoclonal antibody or similar treatments within 4 weeks before starting the study.
• Have had chemotherapy or other cancer treatments within 4 weeks or 5 half-lives of the drug before starting the study.
• Have had radiation therapy within 2 weeks before starting the study.
• Have had a stem-cell transplant within 100 days before starting the study.
• Have had CAR-T cell therapy within 30 days before starting the study.
• Have had an allogeneic stem-cell transplant.
• Have had a solid organ transplant.
• Have a history of hemophagocytic lymphohistiocytosis (HLH).
• Have a history of progressive multifocal leukoencephalopathy (PML).
• Have or have had central nervous system lymphoma or disease.
• Have a history of autoimmune disease.